Cyclobenzaprine treatment for alcohol use disorder

JP2023554597A5Pending Publication Date: 2024-11-26トニックス ファーマシューティカルズ ホールディング コーポレイション
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530204
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-20
Filing Date
2021-11-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is an unmet need to treat symptoms associated with alcohol use disorder (AUD) and improve sleep quality in individuals suffering from this disorder, particularly during and after detoxification.

Method used

Administering a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof, optionally combined with a basifying agent and a pharmaceutically acceptable carrier, via various routes including sublingual, buccal, oral, and transmucosal inhalation, to alleviate symptoms of AUD and related sleep disorders.

Benefits of technology

Cyclobenzaprine effectively reduces alcohol consumption, improves sleep quality, and supports recovery from AUD by ameliorating withdrawal symptoms and cravings, enhancing daily functioning, and promoting safer alcohol use.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides a method for treating alcohol use disorder (AUD) and related symptoms in a subject in need thereof by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable salt comprises a cyclobenzaprine acid salt. The pharmaceutical composition may be administered one or more times daily and may contain between 0.1 mg and 30 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] (Background of the Invention) Cyclobenzaprine, or 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine, was first approved by the US Food and Drug Administration in 1977 for the treatment of acute muscle spasms of local origin. (Katz and Dube, 1988).

[0002] The usefulness of very low doses of cyclobenzaprine as an agent to improve the quality of sleep, as a sleep deepener, or as an agent to treat sleep disorders has been investigated previously. See, for example, US Patent Application No. US20110124656A1, as well as US Patent Nos. 6,395,788 and 6,358,944, which are incorporated herein by reference.

[0003] International Publication No. WO2013 / 188847 (incorporated herein by reference) discloses a low-dose sublingual formulation of cyclobenzaprine (TNX-102 SL) that provides rapid transdermal inhalation into the blood and uniquely reduces the production of norcyclobenzaprine, an active metabolite with a long half-life, by avoiding its first-pass liver metabolism.

[0004] TNX-102 SL contains cyclobenzaprine and a basifying agent. See, for example, WO2013 / 188847, which is incorporated herein by reference. An estimated 36 million adults in the United States have alcohol use disorder (AUD), a chronic relapsing brain disorder characterized by compulsive alcohol use, loss of control over alcohol consumption, and negative emotional states when not using alcohol. There is an unaddressed need to treat the symptoms associated with alcohol use disorder and AUD. As described herein, cyclobenzaprine (e.g., TNX-102 SL) satisfies this unaddressed need and improves sleep quality and success rates in subjects with AUD, as well as in subjects before, during, or after detoxification. [Prior art documents] [Patent Documents]

[0005] [Patent Document 1] U.S. Patent Application Publication No. 20110124656 [Patent Document 2] U.S. Patent No. 6,395,788 [Patent Document 3] U.S. Patent No. 6,358,944 [Patent Document 4] International Publication No. 2013 / 188847 [Overview of the project] [Means for solving the problem]

[0006] (Summary of the invention) This disclosure provides methods for treating alcohol use disorder and related symptoms in individuals requiring treatment.

[0007] The first aspect of this disclosure provides a method for treating alcohol use disorder (AUD) and related symptoms, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a subject in need thereof.

[0008] In some embodiments, the pharmaceutical composition used in the method of this disclosure is administered once a day or more.

[0009] In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises cyclobenzaprine or a pharmaceutically acceptable salt thereof between 0.1 mg and 30 mg. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises cyclobenzaprine or a pharmaceutically acceptable salt thereof between 1 mg and 20 mg. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises less than 10 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises less than 5 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises about 5.6 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises about 2.8 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises about 5.6 mg of cyclobenzaprine salt. In some embodiments, the pharmaceutical composition used in the method of this disclosure comprises about 2.8 mg of cyclobenzaprine salt. In some embodiments, the pharmaceutical composition used in the method of the present disclosure contains about 5.6 mg of cyclobenzaprine acid salt. In some embodiments, the pharmaceutical composition used in the method of the present disclosure contains about 2.8 mg of cyclobenzaprine acid salt. In some embodiments, the pharmaceutical composition used in the method of the present disclosure contains about 5.6 mg of cyclobenzaprine hydrochloride. In some embodiments, the pharmaceutical composition used in the method of the present disclosure contains about 2.8 mg of cyclobenzaprine hydrochloride.

[0010] In some embodiments, the pharmaceutical composition used in the method of the present disclosure is administered as two dose units, each dose unit containing 2.8 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition used in the method of the present disclosure is administered simultaneously as two dose units, the combined amount in the two dose units being 5.6 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition used in the method of the present disclosure is administered once daily.

[0011] In some embodiments, the pharmaceutical composition used in the methods of the present disclosure is administered sublingually, buccally, orally, intravenously, intramuscularly, subcutaneously, by inhalation, intranasally, transdermally, parenterally, rectally, or vaginally. In some embodiments, the pharmaceutical composition used in the methods of the present disclosure is administered by transmucosal inhalation. In some embodiments, the pharmaceutical composition used in the methods of the present disclosure is administered sublingually.

[0012] In some embodiments, the pharmaceutical composition used in the method of the present disclosure comprises a cyclobenzaprine acid salt and further comprises a basicizing agent. In some embodiments, the cyclobenzaprine acid salt is cyclobenzaprine hydrochloride.

[0013] In some embodiments, the cyclobenzaprine in the pharmaceutical composition used in the method of the present disclosure comprises at least a partial eutectic of cyclobenzaprine and mannitol.

[0014] In some embodiments, the pharmaceutical compositions used in the methods of this disclosure are administered in combination with behavioral or environmental interventions.

[0015] In some embodiments, the pharmaceutical compositions used in the methods of this disclosure are administered before, during, or after detoxification. [Modes for carrying out the invention]

[0016] (Detailed description of the invention) Unless otherwise defined herein, scientific and technical terms used in this application have the meanings generally understood by those skilled in the art. In case of any conflict, this specification (including definitions) shall prevail.

[0017] Throughout this specification and its embodiments, the phrase “comprise” or its variations (such as “comprises” or “comprising”) is understood to mean that it includes the integers or sets of integers described, but does not exclude any other integers or sets of integers.

[0018] The terms "including" or "includes" are used to mean "to include, but not to limit to," and "including" and "to include, but not to limit to" are used interchangeably.

[0019] Any examples following the term "e.g." or "for example" are neither exhaustive nor exhaustive.

[0020] Unless the context necessitates a different meaning, singular terms include plurals, and plural terms include singulars.

[0021] The articles “a,” “an,” and “the” are used herein to refer to one or more (i.e., at least one) grammatical objects of the article.

[0022] Although the numerical ranges and parameters disclosed are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. However, any numerical value inherently contains certain errors necessarily resulting from the standard deviation found in its individual test measurements. Further, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed within the recited range. For example, the recited range “1 to 10” is to be considered to include any and all subranges between the minimum value 1 and the maximum value 10 (including the minimum value 1 and the maximum value 10), i.e., all subranges beginning with the minimum value 1 or more (e.g., 1 to 6.1) and ending with the maximum value 10 or less (e.g., 5.5 to 10).

[0023] When aspects or embodiments are described in terms of Markush groups or other groups of alternatives, this application is not limited to including all of the recited groups as a whole, but also includes each element of the group individually, all possible sub-groups of the main group, and also the main group with one or more of its elements missing.

[0024] Exemplary methods and materials are described herein, but methods and materials that are either the same as or equivalent to those described herein may also be used in the practice or testing of various aspects and embodiments. These materials, methods, and examples are merely exemplary and are not intended to be limiting.

[0025] (Definitions) For the present disclosure to be more readily understood, certain terms are first defined. These definitions are to be read in view of the remainder of the disclosure as understood by one of ordinary skill in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Additional definitions are set forth throughout the detailed description.

[0026] In one aspect, this application discloses a method for treating alcohol use disorder and its associated symptoms. In another aspect, the method is used before, during, or after detoxification. The symptoms may be, but are not limited to, sleep disorders or non-sleep disorders.

[0027] The method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine and a pharmaceutically acceptable carrier to a person in need of it or a person at risk of alcohol use disorder and its associated symptoms. The method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine and a pharmaceutically acceptable carrier to a person in need of it or a person at risk of alcohol use disorder and its associated symptoms.

[0028] As used herein, the terms “to treat” and its cognates mean the complete or partial reduction or regulation of alcohol use disorder or at least one identifiable symptom of alcohol use disorder. In some embodiments, “to treat” means an improvement (i.e., a reduction) in the amount of alcohol consumed. In some embodiments, “to treat” means a desire to reduce the amount of alcohol consumed, or an attempt to do so successfully. In some embodiments, “to treat” means spending less time drinking alcohol, or recovering from alcohol use. In some embodiments, “to treat” means feeling a reduced craving or urge to drink alcohol. In some embodiments, “to treat” means being able to better fulfill primary duties at work, school, or home. In some embodiments, “to treat” means improvement from continuing to drink alcohol despite the fact that drinking alcohol causes physical, social, or interpersonal problems. In some embodiments, “to treat” means improvement, i.e., giving up or reducing less social and work activities and hobbies. In some embodiments, “to treat” means improvement, i.e., less alcohol use in situations where alcohol use is unsafe. In some embodiments, “to treat” means improvement, i.e., less alcohol tolerance development. In some embodiments, “to treat” means improvement of withdrawal symptoms (e.g., nausea, sweating, tremors, and sleep disturbances).

[0029] As used herein, the term "cyclobenzaprine" refers to cyclobenzaprine or its metabolites, or prodrugs of cyclobenzaprine or its metabolites. A cyclobenzaprine metabolite useful according to the method of this application is a metabolite that has substantially the same or better activity as cyclobenzaprine in alleviating alcohol use disorder or its associated symptoms. Examples of cyclobenzaprine metabolites that may be useful according to this application include CBP 10,11-trans-dihydril, N-desmethyl-2-hydroxycyclobenzaprine, 3-hydroxycyclobenzaprine, N-desmethylcyclobenzaprine, cyclobenzaprine N-oxide, or chiral isomers of these metabolites. A cyclobenzaprine prodrug is a cyclobenzaprine derivative that is metabolized in vivo to its active substance. A prodrug useful according to this application is a prodrug that has substantially the same or better activity as cyclobenzaprine in treating alcohol use disorder and its associated symptoms. Methods for producing prodrugs are readily known in the art (e.g., Balant et al., 1990 and Bund-gaard, H et al., 1991 (as incorporated herein by reference)).

[0030] In some embodiments of this disclosure, the cyclobenzaprine is combined with a basicizing agent. In other embodiments, the cyclobenzaprine in the combination is an acidic salt of cyclobenzaprine. In other embodiments, the acidic salt of cyclobenzaprine is cyclobenzaprine hydrochloride. See, for example, WO2013 / 188847 (as incorporated herein by reference).

[0031] The “basicizing agent” included in some embodiments of this disclosure is selected from the group consisting of potassium dihydrogen phosphate (monopotassium phosphate, monobasic potassium phosphate, KH2PO4), dipotassium hydrogen phosphate (dipassium phosphate, dibasic potassium phosphate, K2HPO4), tripotassium phosphate (K3PO4), sodium dihydrogen phosphate (monosodium phosphate, monobasic sodium phosphate, NaH2PO4), disodium hydrogen phosphate (disodium phosphate, dibasic sodium phosphate, Na2HPO4), trisodium phosphate (Na3PO4), bicarbonates or carbonates, dipotassium citrate, tripotassium citrate, disodium citrate, trisodium citrate, borates, hydroxides, silicates, nitrates, dissolved ammonia, conjugate bases of some organic acids (including bicarbonate), and sulfides. In some embodiments, the basicizing agent is potassium dihydrogen phosphate (monopotassium phosphate, monobasic potassium phosphate, KH2PO4) or dipotassium hydrogen phosphate (dipassium phosphate, dibasic potassium phosphate, K2HPO4). In some embodiments, the basicizing agent is sometimes a component (and excipient) in the tablet, and the basicizing agent exerts its effect during the time the tablet is dispersed in the mucosal substance, while a portion of the formulation is dissolving in the mucosal substance, and for a certain period after the tablet has dissolved in the mucosal substance. Surprisingly, the addition of a basicizing agent to the composition of the present invention improves the pharmacokinetic properties of the composition. This is exemplified by cyclobenzaprine hydrochloride as one embodiment of cyclobenzaprine useful in the methods and compositions of the present disclosure. A basicizing agent that has a particular effect on cyclobenzaprine hydrochloride is dipotassium hydrogen phosphate (K2HPO4). Another basicizing agent that has a particular effect on cyclobenzaprine hydrochloride is potassium dihydrogen phosphate (KH2PO4). Another basicizing agent that has a particular effect on cyclobenzaprine hydrochloride is disodium hydrogen phosphate (Na2HPO4). Another basicizing agent that has a particular effect on cyclobenzaprine hydrochloride is tripotassium citrate. Another basicizing agent that has a specific effect against cyclobenzaprine hydrochloride is trisodium citrate.

[0032] In some embodiments of this disclosure, the cyclobenzaprine or cyclobenzaprine acid salt (e.g., cyclobenzaprine hydrochloride) is at least partially included in the eutectic system containing mannitol. See, for example, WO2014 / 145156 (as incorporated herein by reference).

[0033] As used herein, the term “eutectic system” refers to a mixture of compounds or elements having a single chemical composition that melts at a lower temperature than the other components of the mixture. A composition containing a eutectic is known as a eutectic composition, and its melting temperature is known as the eutectic temperature. Eutectic compositions often have higher stability and / or dissolution rates than their non-eutectic counterparts. Because eutectic enhances dissolution, eutectic can be used to increase permeability in solid dispersions and solid dispersion systems.

[0034] As used herein, the term "about" refers to a value or parameter that includes (and is described) specific examples relating to the value or parameter itself. For example, a statement referring to "about X" includes a statement of "X". As used herein, the term "about" allows for a variation of ±10% within its significant figures.

[0035] Any suitable route of administration may be used to provide a subject with the pharmaceutical composition of the method of this disclosure. For example, sublingual, buccal, oral, rectal, vaginal, parenteral, transdermal, intranasal, and inhalation may be used when appropriate. As used herein, parenteral includes administration or other infusion techniques to the subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intra-sacral, intrasternal, intrathecal, intralesional, and intracranial regions. Useful dosage forms in the method of this disclosure may include tablets (e.g., scored tablets, coated tablets, or orally disintegrating tablets); films, powders, caplets, capsules (e.g., hard capsules), lozenges, sugar-coated tablets, dispersions, suspensions, liquids, suppositories, patches, etc. (including sustained-release, extended-release, slow-release, and modified-release formulations as are well known in the art). In some embodiments, the dosage form is a sublingual tablet, a sublingual film, a liquid, a sublingual powder, or a sublingual spray liquid. In some embodiments, the dosage form is a sublingual tablet. In some embodiments, the dosage form is a sublingual film. In some embodiments, the dosage form is a sublingual powder. In some embodiments, the dosage form is a sublingual spray liquid. In some embodiments, the dosage form is a liquid.

[0036] In some embodiments, the pharmaceutical compositions of this disclosure are formulated for transmucosal inhalation, and in some embodiments, for sublingual absorption (including sublingual tablets, sublingual film formulations, sublingual powders, and sublingual spray solutions). These embodiments avoid first-pass hepatic metabolism of cyclobenzaprine by cytochrome P-450 3A4 as a CYP3A substrate. In some embodiments, sustained-release pharmaceutical compositions are used in this disclosure. These formulations are capable of releasing cyclobenzaprine at a desired rate into a subject in order to maintain substantially constant or desired pharmacological activity for a predetermined period, to reduce or eliminate the influence of food on absorption, and / or to provide elimination of the drug and its metabolites from the body in a reduced terminal elimination phase. As used herein, “controlled-release component” refers to a compound such as a lipid or lipid mixture, liposomes, and / or microspheres that induces the sustained release of cyclobenzaprine into a subject upon exposure to a particular physiological compound or physiological condition. For example, the sustained-release component may be biodegradable and can be activated by exposure to a specific pH or temperature, by exposure to an aqueous environment, or by exposure to an enzyme. An example of a sustained-release component activated by exposure to a specific temperature is a sol-gel. In this embodiment, cyclobenzaprine is incorporated into a sol-gel matrix that is solid at room temperature. This sol-gel matrix is ​​then transplanted into an object that has a body temperature sufficient to induce the formation of the sol-gel matrix, thereby releasing its active component into the object.

[0037] As used herein, the terms “Alcohol Use Disorder (AUD)” or “Alcohol Dependence” refer to patterns of alcohol use that involve problems with controlling drinking, being addicted to alcohol, continuing to use alcohol even when it causes problems, needing to drink to achieve the same effect (e.g., drinking more frequently and / or drinking larger amounts of alcohol), or experiencing withdrawal symptoms when consumption is rapidly reduced or stopped. AUD can pose health and safety risks.

[0038] As used herein, the term “alcohol intoxication” refers to an increased blood alcohol concentration in the bloodstream. The higher the blood alcohol concentration, the greater the impairment. Alcohol concentration can cause behavioral problems and mental changes, including inappropriate behavior, unstable mood, impaired judgment, slurred speech, attention deficit or memory impairment (e.g., loss of consciousness), and impaired coordination. Very high blood alcohol levels can lead to coma or even death.

[0039] As used herein, the term “alcohol withdrawal” refers to the period of symptomatic experience following the discontinuation or significant reduction of prolonged heavy alcohol use. Alcohol withdrawal may occur within a few hours to four or five days after the reduction or discontinuation of prolonged heavy alcohol use. Signs and symptoms include sweating, tachycardia, tremors of the hands, sleep disturbances, nausea and vomiting, hallucinations, restlessness and agitation, anxiety, and sometimes seizures. Symptoms may be severe enough to impair the ability to function in work or social situations.

[0040] (Alcohol use disorder) Alcohol use disorder (AUD) can be diagnosed by the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM). In DSM-5, anyone who meets any two of the eleven criteria in the same 12-month period is diagnosed with AUD. The severity of AUD ranges from mild (i.e., 2-3 symptoms), moderate (i.e., 4-5 symptoms), to severe (i.e., 6 or more symptoms). Healthcare professionals can assist in the assessment of AUD. Questions to ask during this assessment include: Within the past year, you have 1. Have you ever drunk more or drank for a longer period of time than you intended? 2. Have you ever wanted to reduce or stopped drinking alcohol more than once, or have you tried but been unable to? 3. Did you spend a lot of time drinking alcohol, or did you become ill or overcome any lasting effects from it? 4. Did your desire to drink become so strong that you couldn't think about anything else? (Did you experience a craving for alcohol—a strong desire or urge?) 5. Has drinking—or alcohol-related illness—frequently interfered with caring for your home or family? Or has it caused problems at work? Or at school? 6. Did you continue drinking despite experiencing problems with your family or friends due to your drinking? 7. In order to drink alcohol, have you given up or reduced any activities that are important to you, that you are interested in, or that you find enjoyable? 8. Have you, while drinking or after drinking, engaged in situations that increase your risk of injury (such as driving, swimming, using machinery, walking in dangerous areas, or engaging in unsafe sexual activity) on two or more occasions? 9. Did you continue drinking alcohol despite experiencing mood swings, anxiety, or other health problems as a result? Or did you continue drinking alcohol after experiencing memory loss? 10. Did you have to drink significantly more than before to achieve the desired effect? ​​Or did you find that your usual amount of alcohol produced a much less significant effect than before? 11. When the effects of alcohol wore off, did you notice yourself experiencing withdrawal symptoms such as sleep disturbances, tremors, irritability, anxiety, depression, restlessness, nausea, or sweating? Or did you feel something that wasn't actually there?

[0041] Symptoms associated with alcohol use disorder include: 1) inability to limit the amount of alcohol consumed; 2) desire to reduce or attempt to successfully reduce the amount of alcohol consumed; 3) spending a significant amount of time drinking or recovering from alcohol use; 4) experiencing a strong craving or urge to drink alcohol; 5) being unable to perform primary duties at work, school, or home due to recurrent alcohol use; 6) continuing to drink alcohol despite the fact that consumption causes physical, social, or interpersonal problems; 7) giving up or reducing social and work activities and hobbies; 8) using alcohol in situations where it is unsafe (e.g., while driving or swimming); 9) continuing or increasing consumption to feel the effects of alcohol, or experiencing a decrease in effects from the same amount, as a result of developing tolerance to alcohol; and 10) experiencing withdrawal symptoms (e.g., nausea, sweating, tremors, and sleep disturbances) when consumption is stopped, or drinking to avoid these symptoms.

[0042] (Methods for treatment) Some embodiments of this disclosure relate to methods for treating alcohol use disorder (AUD) and related symptoms, the methods comprising administering a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a subject in need thereof.

[0043] In some embodiments, the pharmaceutical composition is administered once or more times daily. In some embodiments, the pharmaceutical composition is administered once daily. In some embodiments, the pharmaceutical composition is administered twice daily. In some embodiments, the pharmaceutical composition is administered three times daily.

[0044] In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt between 0.1 mg and 30 mg. In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt between 1 mg and 20 mg. In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt between 1 mg and 10 mg. In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt between 1 mg and 20 mg. In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt between 2 mg and 6 mg. In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt less than 10 mg. In some embodiments, the pharmaceutical composition contains cyclobenzaprine or a pharmaceutically acceptable salt less than 5 mg. In some embodiments, the pharmaceutical composition contains about 5.6 mg of cyclobenzaprine or a pharmaceutically acceptable salt. In some embodiments, the pharmaceutical composition contains about 2.8 mg of cyclobenzaprine or a pharmaceutically acceptable salt. In some embodiments, the pharmaceutical composition contains about 5.6 mg of cyclobenzaprine salt. In some embodiments, the pharmaceutical composition contains about 2.8 mg of cyclobenzaprine salt. In some embodiments, the pharmaceutical composition contains about 5.6 mg of cyclobenzaprine acid salt. In some embodiments, the pharmaceutical composition contains about 2.8 mg of cyclobenzaprine acid salt. In some embodiments, the pharmaceutical composition contains about 5.6 mg of cyclobenzaprine hydrochloride. In some embodiments, the pharmaceutical composition contains about 2.8 mg of cyclobenzaprine hydrochloride.

[0045] In some embodiments, the pharmaceutical composition is administered in two dose units, each dose unit containing 2.8 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition is administered in two dose units, each dose unit containing 2.8 mg of cyclobenzaprine salt. In some embodiments, the pharmaceutical composition is administered in two dose units, each dose unit containing 2.8 mg of cyclobenzaprine acid salt. In some embodiments, the pharmaceutical composition is administered in two dose units, each dose unit containing 2.8 mg of cyclobenzaprine hydrochloride. In some embodiments, the pharmaceutical composition is administered simultaneously in two dose units, with the combined amount in the two dose units being 5.6 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition is administered simultaneously in two dose units, with the combined amount in the two dose units being 5.6 mg of cyclobenzaprine salt. In some embodiments, the pharmaceutical composition is administered simultaneously in two dose units, with the combined amount in those two dose units being 5.6 mg of cyclobenzaprine acid salt.

[0046] In some embodiments, the pharmaceutical composition is administered sublingually, buccally, orally, intravenously, intramuscularly, subcutaneously, by inhalation, intranasally, transdermally, parenterally, rectally, or vaginally. In some embodiments, the pharmaceutical composition is administered sublingually. In some embodiments, the pharmaceutical composition is administered buccally. In some embodiments, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is administered intravenously. In some embodiments, the pharmaceutical composition is administered intramuscularly. In some embodiments, the pharmaceutical composition is administered subcutaneously. In some embodiments, the pharmaceutical composition is administered by inhalation. In some embodiments, the pharmaceutical composition is administered intranasally. In some embodiments, the pharmaceutical composition is administered transdermally. In some embodiments, the pharmaceutical composition is administered parenterally. In some embodiments, the pharmaceutical composition is administered rectally. In some embodiments, the pharmaceutical composition is administered vaginally.

[0047] In some embodiments, the pharmaceutical composition is administered by mucosal inhalation.

[0048] In some embodiments, the pharmaceutically acceptable salt is a cyclobenzaprine acid salt. In some embodiments, the cyclobenzaprine acid salt is a cyclobenzaprine hydrochloride.

[0049] In some embodiments, the cyclobenzaprine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition contains at least partially a eutectic comprising mannitol. In some embodiments, the eutectic comprises cyclobenzaprine hydrochloride and mannitol. In some embodiments, the eutectic comprises 75% ± 2% cyclobenzaprine hydrochloride and 25% ± 2% mannitol. In some embodiments, the eutectic comprises 65% ± 2% cyclobenzaprine hydrochloride and 35% ± 2% mannitol. In some embodiments, the eutectic comprises 75% ± 2% cyclobenzaprine hydrochloride and 25% ± 2% β-mannitol. In some embodiments, the eutectic comprises 65% ± 2% cyclobenzaprine hydrochloride and 35% ± 2% δ-mannitol.

[0050] In some embodiments, the pharmaceutical composition is administered in combination with behavioral or environmental interventions. In some embodiments, the pharmaceutical composition is administered before, during, or after detoxification.

Claims

1. 1. A pharmaceutical composition for treating alcohol use disorder (AUD) or one or more associated symptoms thereof in a subject in need of treatment thereof, the pharmaceutical composition comprising cyclobenzaprine or a pharma- ceutical acceptable salt thereof and a pharma- ceutical acceptable carrier.

2. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered one or more times daily.

3. The pharmaceutical composition comprises: (a) between 0.1 mg and 30 mg of cyclobenzaprine or a pharma- ceutically acceptable salt thereof; (b) between 1 mg and 20 mg of cyclobenzaprine or a pharma- ceutically acceptable salt thereof; (c) less than 10 mg of cyclobenzaprine or a pharma- ceutically acceptable salt thereof, or (d) less than 5 mg of cyclobenzaprine or a pharma- ceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 1 or 2, comprising:

4. A pharmaceutical composition according to any one of claims 1 to 3, wherein the pharma- ceutically acceptable salt of cyclobenzaprine is cyclobenzaprine hydrochloride.

5. The pharmaceutical composition for use according to claim 4, wherein the cyclobenzaprine hydrochloride is in the form of a mannitol co-crystal.

6. The pharmaceutical composition for use according to claim 5, wherein the mannitol eutectic is a eutectic of 75% ± 2% by weight cyclobenzaprine hydrochloride and 25% ± 2% by weight β-mannitol, or a eutectic of 65% ± 2% by weight cyclobenzaprine hydrochloride and 35% ± 2% by weight δ-mannitol.

7. The pharmaceutical composition of any one of claims 4 to 6, wherein the pharmaceutical composition comprises 5.6 mg of cyclobenzaprine hydrochloride.

8. The pharmaceutical composition of any one of claims 4 to 6, wherein the pharmaceutical composition comprises 2.8 mg of cyclobenzaprine hydrochloride.

9. 9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is administered as two dosage units, each dosage unit containing 2.8 mg of cyclobenzaprine hydrochloride.

10. 10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is administered simultaneously as two dosage units, the combined amount in the two dosage units being 5.6 mg of cyclobenzaprine hydrochloride.

11. The pharmaceutical composition of any one of claims 4 to 10, further comprising a basifying agent.

12. The pharmaceutical composition of claim 11, wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, bicarbonate or carbonate, dipotassium citrate, tripotassium citrate, disodium citrate, and trisodium citrate.

13. The pharmaceutical composition of claim 12, wherein the basifying agent is dipotassium hydrogen phosphate.

14. The pharmaceutical composition according to any one of claims 1 to 13, characterized in that the pharmaceutical composition is administered once a day.

15. The pharmaceutical composition according to any one of claims 1 to 14, characterized in that said pharmaceutical composition is formulated for transmucosal absorption.

16. The pharmaceutical composition described in claim 15, wherein the transmucosal absorption is sublingual absorption.

17. The pharmaceutical composition of any one of claims 1 to 16, characterized in that the pharmaceutical composition is formulated as a tablet, suppository, film, thin film, liquid, powder, or spray liquid dosage form.

18. The pharmaceutical composition according to any one of claims 1 to 17, characterized in that said pharmaceutical composition is administered in combination with a behavioral or environmental intervention.

19. The pharmaceutical composition according to any one of claims 1 to 18, characterized in that said pharmaceutical composition is administered before, during or after detoxification.